Process for preparing 2-amino-3-carbethoxyamino-6-(n-fluorobenzylamino)pyridine maleate

专利摘要:
There is prepared 2-amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate of the formula <IMAGE> The compound has antiphlogistic and analgesic properties in the same manner as the known hydrochloride salt. In contrast to the hydrochloride 2-amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate can be produced without a disturbing blue coloration. This maleate generally is formed from a mixture of two crystal modifications A and B, whereby there is especial advantageous in regard to isolation as well as the galenical preparations a mixture entriched in modification A (60 to 90% modification A).
公开号:SU1091855A3
申请号:SU813332400
申请日:1981-09-10
公开日:1984-05-07
发明作者:Фон Бебенбург Вальтер (Наследница Мария Фон Бебенбург)；Паулун Зигфрид
申请人:Дегусса Аг (Фирма)；
IPC主号:

专利说明:


iSS
ate
SP
2. A method according to claim 1e about tl and h and y and the fact that the interaction of 2 - amino-3-carbethoxyamide: o-6- (p-fluoro benzylamino) pyridine with maleic acid is carried out at 20 - 60 ° C if necessary with the addition of seed crystals.
3, the Method according to PP. 1 and 2, about tl and cussed by the fact that 2-am: alko-3-carbethoxyamino-6- (p-fluorobenz5-shami but) pyridine before interacting with
maleic acid is treated with activated carbon.
4. The method according to paragraphs. 1-3 j o t l and t that, in order to isolate the target product with the content of crystalline modification A not less than 60%, the crystallized maleate is heated in the presence of an inert solvent used at a temperature from 30 ° C to the boiling temperature of the solvent for 5-180 min
This invention relates to a process for the preparation of a new salt of 2-amino-3-carbyH2-1 with a predominantly anti-inflammatory and analgesic activity, Poicer may find use in medicine.
A known method for the production of 2-amino-3-carbethoxyamino-6- - (p-fluorobenzylamino) pyridine hydrochloride hydrochloride having anti-inflammatory and analgesic activity by hydrogenating 2 amino-3-nitro &amp; g (fluorobenzylamino) pyridine in the presence of Retse nickel followed by interaction of the obtained compound p-: with ethyl ether of chloroformic acid C 1.
However, as a result of this process, intensely blue-colored hard-to-avoidable side products are formed.
The purpose of the invention is to obtain a new salt of 2-amino-3-carbztoxy-amyg-6- (p-fluorobenzylamino) pyridine.
This goal is achieved by the fact that according to the method of obtaining 2-amino-3-carbethoxyamn-6- (p-fluorobenzylamino) pyridine maleate 1 mole of 2-amino-3-carbethoxyamino-6 (p-fluorine benzylamino) pyridine in an inert solvent is brought into interaction with
1.1-1.5 mol of maleic acid at
0 temperature from 20 ° C to teterature
boiling of the solvent and the target proethoxyamino-6- (p-fluorobenzylamino) pyridinag e. it is his maleate formula
- H-woc, H, j ,.
"2. KJ-COOH
The product is isolated as a mixture of two crystalline modifications, A and B,
In this case, modification A is characterized by the absorption band in the IR spectrum at 1170 cm S modification B by the absorption band at 1160.
Preferably interaction
J 2-amino-3-carbethoxyamico-6- (p-fluorobenzylamino) p 4-yridine with maleic acid is carried out at 20-60 ° C, if necessary with the addition of seed crystals.
Q 2-A1MnO-3-carbethoxyamino-6- (n fluorobenz {-samino) pyridine is treated with activated charcoal before interaction with maleic acid. In order to isolate a target product with a crystalline codification A of at least 60%, the crystallized mapat is heated in the presence of an inert solvent used at a temperature of from 30 ° C to
g boiling point of the solvent for 5-180 minutes.
The resulting 2-amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine maleate has anti-inflammatory and analgesic activity, is isolated as a mixture of two crystalline modifications of A and B, and is convenient for preparing pharmaceutical preparations. A mixture of crystalline modifications A and B may contain 0-50% modification A (the rest is modification B). At the same time, the target product can be made in a paste-like or fiber shaped form. Mixtures of modifications containing 6090%, preferably 65-85%, modifications A (the rest of modification B) crystallize in the form of short needles, which are easily separated. Such mixtures have the following advantages: they have better flowability, they require less lubricant (magnesium stearate) in the manufacture of tablets, and crystals also have better wettability. The best results were shown by mixtures of crystalline modifications with the content of modifications A 70–85%, better 75–85%, in particular 78–82%. In order to obtain a mixture of crystalline modifications, the concentration of 2-amino-3-carbethoxygmino-6- (p-fluorobenzyl-1-amino) pyridine and maleic acid used in the inert solvent used for this temperature is conveniently selected so that crystallization of the maleate starts immediately after mixing these reagents. For example, a solution of pyridine base in iso-propanol or ethanol is used, which contains, for example, 1 kg of pyridine base in 35-38 l of isopropanol. A corresponding amount of maleic acid (1.1-1.5 mol per 1 mol of base) is added as a solution in an inert solvent, preferably in isopropanol or ethanol, which contains 1–9 liters of alcohol 1 kg. maleic acid. If the reaction of 2-amino-3-carbethoxy amino-6- (p-fluorobenzylamino) pyridine with maleic acid proceeds at a temperature of more than 60 ° C, a mapat is obtained which consists of pure modification B or enriched with modification B. be converted to modification A or to a mixture with a predominant amount of modification A. For example, lower aliphatic C-j-C alcohols (preferably with a minimum number of carbon atoms 2: ethanol, isopropanol) are used as a solvent to produce maleate; esters of esters (pyoxan, tetrahydrofu 55 wounds), dipolar aprotic solvents, such as amnds,.-alkylamides or C-C dialkylamides of aliphatic. -carboxylic acids (dimethylformamide, dimethylacetamide), tetramethylurea, sulfolane or dimethyl sulphoxide. These solvents can also be used as mixtures with each other, as well as as a mixture with water. To eliminate the appearance of (in some cases) blue dyeing, the base is separated from the crude maleate in the usual manner, and it is advisable to work in a nitrogen atmosphere. This base is then dissolved in a conventional solvent (isopropanol, ethanol, methanol), mixed with 3-12, preferably 5-10 wt.%, Activated carbon (calculated as base) and heated briefly (5-20, preferably 10 minutes). at 50-80 ° C, preferably at 65-70s. Then filtered from the coal. This carbon treatment can also be combined with recrystallization, i.e. 2-amino-3-carbethoxy-6- (p-fluorobenzylamino) pyridine, in the presence of the same amount of activated carbon, is recrystallized from the above solvent under known conditions when water is added (expediently under an atmosphere of nitrogen), and the solution must be in contact with coal maximum 10 min. Preferably, such recrystallization is carried out from isopropanol. As activated carbons, for example, activated plant-wood carbons are used, which are prepared by pure activation with water vapor and, under certain conditions, by additional treatment with mineral acid and deionized water are brought to a very low ash content, i.e. low in heavy metachlores. Medical coal powders with the following pore distribution are suitable: micropores (diameter 0-20 A) 0.6 ml / g; mesopores (diameter 20-300 A) 0, J5 ml / g; macropores (diameter over 300 A) 0.5 ml / g. Also used are washed treated with mineral acid and deionized water and brought to a powdery state decolorized; activated carbons having, for example, the following pore distribution: micropores of 0.2-0.4 ml / g, in particular 0.4 ml / g; mesopores of 0.2-0.5 ml / g, in particular 0.2 ml / g; Macropores of approximately 0.5 ml / g, in particular O5 5 ml / The removal of the base maleate from the base is carried out in a known manner, for example, by treating the maleate in the indicated solvent (preferably isopropanol, ethanol) with basic substances, such as ammonia, tertiary amines (lower trialkylamines, for example, triethylamine), carbonates of alkali metals, alkali hydroxides at 10–40 ° C, preferably metals but 20–30 ° C, especially 20–25 ° C. A mixture containing 60–90% of crystalline modification A, for example, can be obtained by the interaction of 2-amino-3-carbat ksiamino-6- (p-fluorobenzylamino) pyridine with maleic acid in the presence of insoluble seed crystals. Preferably, however, modification A or crystals of the mixture A rich in modification A is used as seed crystals. In this way, a mixture is obtained, containing 60-90%, for example 70-85% J modification A. A mixture with a predominant proportion of modification B (for example, 90-55%) or a mixture with a high proportion of A (for example, 60-90%) by heating without solvent at 40-180, preferably 80-150 ° C, in particular 80-130 ° C, can be converted into a mixture with a high content of modification B (11-100%) or even into a pure modification B, It is advisable that the mixture is constantly stir (eg shake). The duration of such a conversion may be, for example, from 10 minutes to 14 days. Properties of crystal modification B, as well as mixtures of both crystal modifications A and B. o Modification V. T. pl. 177.7-1775 (MettJer FP-1 instrument), 177.3 ° C (differential calorimetry) IR spectrum in KBG presented on. FIG. 6-8; FIG. 8, increased from the sharply indicated spectrum in FIG. / In the region 1100-1200, where the characteristic bands for modifications A and B are. The maxima in the IR spectrum are: 3318, 3179, 1691, 1658, 1512, 1348, 1270, 1229, 1158, 1120, 1071, 861, 821, 779, 650 cm-1. The proportion of modifications A and B in mixtures is determined by quantitative IR spectroscopic analysis. Pure modification B is characterized by an absorption band at 1160 cm, pure modification A is at 1170 cm. Mixtures consisting of modifications A and B, according to their composition, are characterized by the simultaneous presence of both bands in a weakened form. From the ratio of the height of the bands, one can calculate the fraction of Au and B, respectively. To conduct IR spectroscopy, tablets with KBr are prepared. When mixing and grinding KBr and 2-amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine maleate without a solvent, the transformation of modification A into modification B may occur. Therefore, it is necessary to produce KBr pressing as follows. Sample: 0., 8 - 1.0 mg of 2-amino-3-carbethoxy-amino-6- (p-fluorobenzylamino) pyridine maleate and 300 mg KBr. Milling and mixing: an electromechanical vibrating mill with a consumed power of 300 (Perkin Elmer); chrome steel capsule with steel &amp; 1 ball; grinding time is not more than 15 seconds, better than 10-15 seconds. Pressing: 13 mm (mold SPEAC F, OrieE), deaeration 2 minutes at 5 torr; pressing for 2 minutes using 8 tons. IR absorption and evaluation: The instrument is a diffraction spectrophotometer 521 (Perkin Elmer): the extension of the y-axis is 1x; (slit) S it-program - 10; gain factor 3; speed attenuator 11; scan time - 2/2; suppression - 5; signal amplitude amplification: resonance - 3. In order to increase the bandwidth for better evaluation, the louver diaphragm is used, in the comparative beam at 1140 cm the ordinate is set at 90-100% transmission or 0.0-0.01 extinction and Then the area of 1220–1130 cm is registered. The estimated height of the bands is both minimum and 1140 cm is connected to each other 1180 and the height of the bands at 1170 and the other. –1 1160 is measured with respect to that connecting line. FIG. Figures 1 and 2 show an IR-spec mixture with 80% modification A; Fig. IR spectrum of pure modification B. Calculation of the content in the mixture of modification A based on the spectrum for pure modification i B (see Fig. 1-3, as well as Fig. 8) is carried out according to the following formula B d -100 where B d - strip height at 1170 cm hg - strip height at 1160 cm. The standard deviation of SA is 5%. Maleate mixtures with different contents of both crystal modifications A and B, besides the IR spectrum, can also be characterized by a specific melting region. The melting areas for mixtures of certain compounds are presented below (the melting point was determined using a Mettger FP-1 instrument): A - B,% Starting 2-amino-3-carbethoxyam-but-6- (P-fluorobenzylamino) pyridine is the result from 2,6-dichloro-3-pyridine nitrate through 2-amino-3-nitro-6-pyridine by further interaction of the latter compound with p-ft benzylamine, subsequent reduction to 0 60 l
Lenin nitro groups to the amino group and acylations of the amino group using ethyl chloroformate.
If the basic substance is not used in the reaction with chloroformic acid ethyl ester, then hydrochloride is obtained, where the free base is obtained by treating it with basic substances (tertiary amines, for example, triethylamine). For example, in a solution of 21.3 kg of 2,6-dichloro-3-nitropyridine (90% wet) in 100 l of isopropanol, while moving at 20-30 s, 55 6.8 kg (400 mol) of gaseous ammonia are passed ( also drop in ammonia solution). Then the reaction mass
Magnesium sulfate and 2 kg of Rene nickel are hydrogenated under a pressure of 2-30 bar at 60-80 ° C. The solution is filtered in the absence of air. After the next 30 liters of dioxane is added (serves to wash the filter cake), 7.7 liters of ethyl chloroformate and 10.7 liters of triethylamine are added dropwise to the filtrate under nitrogen and cooled (exothermic). The temperature is allowed to approximately 75 ° C. Then stirring is continued for 2 hours. If the temperature of the reaction mass reaches 30 ° C, then it is cooled with cold water.
The breakdown of 2-amino-3-carbethoxyamino-b- (p-fluorobenzylamino) pyridine is carried out, for example, via maleate. pereemigat 24 h at room temperature. The resulting 2-amino-3-nitro-6-chloropyridine is reacted as a slurry after the unreacted 2,6-dichloro-3-nitropyridine test has shown negative results using a thin layer or gas chromatography. With a suspension of 2-amino-3-nitro-6-chloropyridine, a solution of p-fluorobenzylamine in isopropanol (obtained below) is added at room temperature with stirring. 22.3 kg of triethylamine are then added dropwise and the mixture is stirred for 6 hours at reflux temperature. 100 liters of water are then added and 2-amino-3-nitro-b- (p-fluorobenzylamino) pyridine precipitates out, which is sucked off, washed with isopropanol and dried (yield 21 kg, mp. 179-181 ° C). The p-fluorobenzylamine solution is prepared as follows. A solution of 18.6 kg of p-fluorobenzaldehyde in 60 liters of isopropanol in an autoclave under nitrogen is mixed with 4 kg of Rene nickel. 10.2 kg of ammonia are passed through and the closed autoclave is heated for 3 hours with stirring at. Then it is purged with nitrogen and hydrogenated at 50-65 ° C under a pressure of 5-10 bar of hydrogen. After the uptake of hydrogen is complete, stirring is continued for another 1 h. It is filtered off from the catalyst, and the resulting solution is directly processed further. 17.6 kg of the resulting 2-amino-3-nitro-6- (p-fluorobenzylamino) pyridine in dioxane with the addition of 12 kg After hydrogenation, the mixture obtained is filtered through a pressure filter and mixed with 510 l of isopro-panol at 25, then added another 30 liters of isopropanol, which were used to filter the precipitate. After hydrogenation, this solution is poured, with stirring, to a heated solution of 12 kg of maleic acid in 60 liters of isopropanol (advantageously in several batches). The maleate formed immediately precipitates. pH should be 3-4. The resulting suspension is cooled to about 20 ° C, centrifuged and washed with 30 L of isopropanol. The crude maleate by subsequent heating (for example, in isopropanol), as indicated above, can be converted into a mixture enriched in modification A (for example, 60-90% of modification A). Moreover, heating under the known conditions can be repeated twice. Preferably, crude maleate (32.66 kg, wet from isopropanol, 74.5%) in an apparatus in which 50 liters of isopropanol are previously placed, with stirring, using 2 and 1 of aqueous concentrated ammonia is transferred to the free base (and maleate and ammonia are introduced alternately). The process is conducted in a nitrogen atmosphere. After adding maleate and ammonia, 61 L of water is added and additionally stirred for 1 hour. Free base of 2-amino-3-carbethoxyamino-b- (P-fluorobenzylamino) pyridine is isolated by centrifugation, washed with water until neutral, and dried in vacuum at 55 ° C, so pl. 117-120 ° C. A thin layer chromatogram (eluent: methanol: chloroform 8: 2) shows the main spot at R = 0.72, as well as two trace additional spots: Rr 0.78 and 0.80. , .IR spectrum in KBG Gfig. 4 and 5) shows the maxima at: 3371, 3360, 3200, 2982, 1698, 1621, 1505, 1425, 1286, 1255, 1220, 1162, 1105, 1073 ,, 850, 838, 803, 584, 497 cm-t. The IR spectrum does not change if this raw base is treated, as indicated above, with active carbon (for example, for 10 minutes in isopropanol at 50-60 ° C), only both additional spots in the thin layer chromatogram become even weaker, and so on. now 55 after the previous calcination () is 117 ° C. The 5% solution in ethanol has a green color, which is enhanced for 12 hours with air. The resulting crude 2-amino-3-carbethoxyakino-6- (p-fluorobenzylamino) pyridine base can be used, after the described purification with activated carbon, directly to produce colorless maleate. The parent base can be obtained from 2-amino-3-carbethoxyamino-6- (p-fluorobenzyl | But) pyridine hydrochloride (mp 214-215 ° C) by treatment with a base (tertiary amines, for example, triethylamine; carbon alkali metals, alkali metal hydroxides) in a common solvent or suspending agent. For example, raw base with so pl. 117 can be obtained from the hydrochloride in methanol solution by adding aqueous ammonia. The base of 2-amino-3-carbethoxyamino-6-1, p-fluorobenzylamino) pyridine can be recrystallized in the presence of activated charcoal. To do this, 15.9 kg of the crude base are dissolved under nitrogen in 48 liters of isopropanol at 75 ° C, mixed with activated carbon, and filtered after 10 minutes. With irregular stirring, crystallization occurs. The base is separated by centrifugation, washed with 5 L of isopropanol and dried under vacuum at 55 ° C. In the thin-layer chromatogram, the main spot is found at R 0.72, as well as very weak traces of two additional spots (Rf 0.7 § and 0 , 80). The IR spectrum is identical to the IR spectrum of the crude base (Fig. 4 and 5). The 5% solution of base in ethanol is colorless; for 20 hours, with the access of air, it turns green. The base described is also suitable for the preparation of pure maleate and the corresponding mixture of modifications. The following method is most preferred, 2-Amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine, as indicated, is converted into maleate. A base (crude) is prepared from the maleate, which, as indicated, is treated with activated carbon and / or recrystallized in the presence of activated io coal. The resulting base is again, as indicated, expediently under an atmosphere of nitrogen, transferred to maleate. Example 1. Preparation of a pure crystalline determination of B 2-amino-3-carbethoxyamino-6- (p-fluorobenzyl amino) pyridine maleate. A solution prepared at 60 C of 30.0 g (0.1 mol) of 2-mino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine (crude base, mp, calcined at 115 C) in isopropanol for 10 min at 50-60 ° C is treated with activated carbon. The base described has Rr 0.72 in methanol: chloroform 8: 2. IR spectrum in KBG (Fig. 4 and 5), maxima at: 3371.3360, 3200, 2982, 1698, 1621, 1505, 1425, 1286, 1255, 1220, 1162, 1105, 1073, 850, 838, 803, 584, 497 cm-h. 1080 ml of isopropanol is mixed with a solution of 12.8 g (0.11 mol) of maleic acid in 96 ml of isopropanol at 60-62s, which contains seed crystals of modification B. It is cooled to 17 ° C and the crystallized compound is separated by centrifugation. Seed crystals of modification B are obtained, for example, by dry heating of the maleate mixture obtained according to Example 4 for 2 hours at 150 ° C in a dried state. Output 96.6% of theory. M.p. 177, 177, (MettBer FP-1 device). The IR spectrum in KBG is presented in FIG. 6-8. Example 2. Preparation of 2-amino-3-carbztoxyamino-6- (p-fluorobenzylamino) pyridine maleate with a content of crystalline modification A 80% (error limit + 5%). 2-amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine (crude base, mp. 117 s) is calcined at 115 ° C. .. R 0.72 in methanol: chloroform 8: 2. The IR spectrum in KBG is presented in FIG. 4 and 5, the maximums at: 3371, 3360, 3200, 2982, 1698, 1621, 1505, 1425, 1286, 1255, 1220, 1162, 1105, 1073, 850, 838, .803, 584, 497 cm-1. 30 g (0.1 mol) of this base are dissolved at 65 ° C in 1100 ml of isopr panol, cooled to 2 ° C and mixed with stirring with a solution of 12.8 g (0.11 mol) of maleic acid in 98 ml of isopropanol at 25 ° C. The precipitated maleate precipitate of the maleate is heated at 60 ° C for 60 minutes, allowed to cool to 25 ° C and separated by centrifugation. Output 96% of theory. Mp.175.2175, 7 (Mettler FP-1 device). The resulting maleate contains 80% of crystal modification A and 20% of crystal modification B (error limit J is 5%). The IR spectrum in KBG is presented in FIG. 9-11. Example 3. Obtaining 2-amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine maleate with a crystalline content of A 71% (error limit -f 5%). A solution prepared with 65 C of 45 g of 2-amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine (the base is prepared as in Example 2) in 1626 ml of ethanol is mixed with a solution of 18.9 g of maleic acid in 146 ml of stanol, to which seed crystals are added with an enriched modification of A mixture (A content 80%, obtained according to example 2). The reaction mass is cooled to 8 ° C and the precipitated compound is separated by centrifugation. Output 94.1% of theory. Mp.176.5176, 7 s (Mettfer FP-1 device). The IR spectrum in KBG is presented in FIG. 1214, maximums at: 3430, 3300, 3218, 1920, 1710, 1645, 1630, 1571, 1520, 1090, 1362, 1280, 1229, 1170, 1127, 1076, 970, 865, 656 cmH. Example 4. Preparation of 2-amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine maleate with a crystalline modification A content of 84% (error limit + 5%). To a heated 500-liter container, containing 370 l of isopropanol, 43.0 kg (141.29 mol) of 2-amino-3-carbethoxy-amn-6- (p-1) are added with stirring, passing nitrogen and heating to 50 ° C. fluorobenzylamino) pyridine (base, see example 2), the mixture was heated to 70 ° C. After adding 4.3 kg of activated carbon in 13 liters of isopropanol, the solution was kept at 70 ° C for 10 minutes and filtered under nitrogen on a filter that worked under pressure. 13 The filtrate in a nitrogen atmosphere is immediately transferred to the machine with a stirring capacity of 2000 liters, where 1151 isopropanol is located. The temperature of the solution is set and a solution of 18.04 kg of maleic acid in 138 l of isopropanol is added under nitrogen atmosphere. Maleate is dissolved in loose form, it is heated for 2 hours at 60 ° C, cooled to 18-20 ° C, maleate is separated centrifuged and washed with ice-cold isopropanol (15 L x 3). The isolated compound is dried in vacuo at 50 s. Output 95% of theory. The resulting maleate consists of 84% crystalline modification A, mp, 175.7 - 176.0 C (MettBer FP-1 device). The IR spectrum in KBG is presented in FIG. 15-17, maximums at: 3430 3300, 3218, 1920, 1710, 1645, 1626, 1571, 1520, 1390, 1361, 1280, 1229, 1170, 1126, 1076, 970, 855, 653 Example 5. Preparation of 2-amyio - 3-carbethoxyamino-6- (p-fluorobeneyl-amino) pyridine maleate with the content of crystal modification K 117: (error limit + 5%). A solution prepared at 60 ° C with 45 g of 2-amino-3-carbethoxyamino-6- (p-fluorobacZylamino) pyridine (base, see Example 2) in 1626 ml of isopropanol is mixed with a rastor of 18.9 g of maleic acid in 146 ml of isopropanol, to which are added undissolved seed crystals enriched with modification A of the maleate mixture (80% of modification A, prepared according to example 2). The reaction mass is cooled to 18 ° C and the crystallized compound is separated by centrifugation. Yield 94.1% of theory. Mp.175.6P6 (Mettler FP-1 instrument). The IR spectrum in KBG is presented in FIG. 18-20. The resulting 2-amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine maleate has the same activity as the hydrochloride of the indicated compound, but is more physically suitable for the preparation of pharmaceutical preparations, it is released in its pure form.
1170 air defense
h, /, 1160
FIG. 2
Cpvi 3 I I I 1 I I I I I 1. . I I I I I. I 11111
N5%
Sh
"VJ
s Q .1



0 / Q dnHo j / itJodu M-l I. -. I I M I I I I I
4i
S e Pass / e I § PP
 J300 then rooo
fC /
Fig.8

: II II tI
CH1IfI
-i IMI
1 i I I i-: C Ir ± -r1 I
I, t i%

“O
Cvj
cs;
§
s


%, 11 Transmission,% 11 1 I I f I I I I 1 1 1 I I I I I I I-I I I I I I 1 1 I I I
h
5s QI II I II I II I G1-H-- II II I H i
gzoo
I, M ((P
100
1200 tt gt
FIG. //
CM
% 3nMD fJ UOClU
o / elio / zyo ts
o 1300 1200 1100 woo
Yu
X, Hf№f
100
70
l
"
-.0
-r
Cpvz 1 Transmission, S% I I I IO-,, I I I I I I I I I I I I I I
A, MKfi 100
 I
i
"H
about iSx
so
then that
ABOUT
t smpooo
gooo
-, 17
Cs,

Lopuskan1e,% -il I I I I M I I I I I I I I I I 1 I I I I I I Mil A 11 I I ft. t 11 II

权利要求:
Claims (3)
[1]
1. METHOD FOR PRODUCING 2-AMIN0-3-CARBETOXYIAMINO-6- (P-fluorobenzylamino) pyridine maleate of the formula
Oh ^CH * ^_yan AA _TA2
Ηΰ- € 00Η
I non-eOon characterized in that
1 mol of 2-amino-3-carbethoxyamino-6- (p-fluorobenzylamino) pyridine in an inert solvent is reacted with 1.1-1.5 mol of maleic acid at a temperature of from 20 ⁰ C to the boiling point of the solvent and the target product is isolated in the form of a mixture of two crystalline modifications A and B, while modification A is characterized by an absorption band in the IR spectrum at 1170 cm “ ¹ , modification B is characterized by an absorption band at 1160 cm ~ 1.
777/7 1160
FIG. 1
[2]
2. The method according to π. 1, with the fact that the interaction of 2-amino-3-carbethoxyamino-6- (p-fluoro ~ benzylamino) pyridine with maleic acid is carried out at 20-60 ° C, if necessary, with the addition of zat equal crystals.
[3]
3. The method according to PP. 1 and 2, with t l, characterized in that 2-amino ~ 3 ~ -carbethoxyamino-6- (p-fluorobenzylamino) pyridine is treated with activated carbon before reacting with maleic acid.
h. The method according to PP. 1-3-, characterized in that, in order to isolate the target product with a content of crystalline modification A of at least 60%, the crystallized maleate is heated in the presence of an inert solvent at a temperature of 30 ° C to a boiling point of the solvent for 5-180 minutes.
ί

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1091855A3|1984-05-07|Process for preparing 2-amino-3-carbethoxyamino-6-|pyridine maleate

---

SU1634138A3|1991-03-07|Method of producing guanine derivatives or their acid=additive salts suitable for pharmacy

---

RU2078079C1|1997-04-27|Derivatives of pyrrole-substituted ureides and their pharmaceutically acceptable salts, method of their synthesis and pharmaceutical composition showing angiotensin inhibiting activity

---

EP0737686B1|1999-07-07|Camthothecin derivative with antitumor activity

---

BG63893B1|2003-05-30|New modifications of 2-amino-4-|-1-ethoxycarbonylaminebenzene and methods for their preparation

---

EP0041355A1|1981-12-09|Novel erythromycin compounds

---

EP0165574B1|1992-08-19|Method for production of maleimides

---

DE2821403C2|1984-01-26|Decahydronaphthalene-1-spiro-2&#39;-dihydrobenzofurans, processes for their preparation and pharmaceutical compositions containing these compounds

---

AU2011201257B2|2013-03-21|Salt of |-3-[[|-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid

---

CN110511156A|2019-11-29|A kind of preparation method of di-lysine-aspirin

---

EP0611369B1|1999-07-28|Process for preparing | |-4,4&#39;-|-bis|

---

US4870178A|1989-09-26|Process for the obtention of the ethyl ester of the apovincaminic acid

---

WO2021043200A1|2021-03-11|Method for preparing quinazoline derivative and crystallization thereof

---

AU2020229932A1|2021-09-23|Salt of aldose reductase inhibitor, and preparation method and application thereof

---

SU1443801A3|1988-12-07|Method of producing |-3s,16r,14r-14,15-dihydro-14-hydroxymethyl-eburineamenine

---

KR100257967B1|2000-07-01|Process for the preparation of pyridoxine 5-oxo-2-pyrrolidone carboxylate

---

KR910008111B1|1991-10-10|Process for the preparation of erythromycin salt with 5-|-alpha,alpha,4-trimethyl-3-cyclohexene-1-methanolic acid

---

SU679583A1|1979-08-15|Method of obtaining derivatives of phenothiazine

---

SU1564992A1|1992-07-07|Method of producing 1-amino-2h-5,6-dioxo-1,2,3-triazine

---

CN113620868A|2021-11-09|Torasemide new impurity and preparation method thereof

---

CN114085214A|2022-02-25|Sofantinib impurity and preparation method and application thereof

---

SU1578135A1|1990-07-15|Method of obtaining acetilized nucleosides

---

AU2019350699A1|2021-04-08|Process of making calcium alpha-ketoglutarate

---

SU1015598A1|1989-09-15|Method of producing 0-|-phenylpropiophenon hydrochloride

---

WO1988000198A1|1988-01-14|Antitumor alkaloids

同族专利:

---

公开号 | 公开日

---

ZA816336B|1982-09-29|

---

NL8104211A|1982-04-01|

---

AR229101A1|1983-06-15|

---

CH646952A5|1984-12-28|

---

BE890331A|1982-03-11|

---

IE812055L|1982-03-13|

---

AT375924B|1984-09-25|

---

CA1147736A|1983-06-07|

---

ES505423A0|1982-08-16|

---

NL189856B|1993-03-16|

---

HU182720B|1984-03-28|

---

FR2490225B1|1985-09-06|

---

AU7516381A|1982-03-25|

---

DD201786A5|1983-08-10|

---

DK159878C|1991-05-13|

---

ES8206481A1|1982-08-16|

---

SE454693B|1988-05-24|

---

FI812836L|1982-03-14|

---

SE8105425L|1982-03-14|

---

IT8149272D0|1981-09-11|

---

PL130030B1|1984-07-31|

---

GB2084138B|1984-07-25|

---

EG15446A|1986-06-30|

---

NO813082L|1982-03-15|

---

US4481205A|1984-11-06|

---

NL189856C|1993-08-16|

---

JPS5781465A|1982-05-21|

---

KR830007556A|1983-10-21|

---

GR75777B|1984-08-02|

---

GB2084138A|1982-04-07|

---

CS226037B2|1984-03-19|

---

LU83633A1|1982-01-21|

---

NO160919B|1989-03-06|

---

NO160919C|1989-06-14|

---

IN155674B|1985-02-23|

---

YU215781A|1984-02-29|

---

IT1171520B|1987-06-10|

---

ATA393481A|1984-02-15|

---

FI79531B|1989-09-29|

---

YU43037B|1989-02-28|

---

PL232999A1|1982-08-16|

---

KR860000585B1|1986-05-17|

---

DK404681A|1982-03-14|

---

DK159878B|1990-12-24|

---

FI79531C|1990-01-10|

---

AU541020B2|1984-12-13|

---

FR2490225A1|1982-03-19|

---

IE51547B1|1987-01-07|

---

JPH0259149B2|1990-12-11|

---

IL63801D0|1981-12-31|

---

IL63801A|1984-10-31|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

DE1795858C2|1968-07-19|1979-01-11|Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt|Benzylaminopyridines|

---

US3969361A|1972-05-10|1976-07-13|Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler|2-Benzoyl-3-amino-pyridines|DE3416609A1|1984-05-05|1985-11-07|Degussa Ag, 6000 Frankfurt|2-AMINO-3-ETHOXYCARBONYLAMINO-6-- PYRIDINE GLUCONATE AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THIS SUBSTANCE|

---

NO860825L|1985-03-23|1986-09-24|Degussa|PROCESS FOR PREPARING 2-AMINO-3-NITRO-6--PYRIDINE AND 2-AMINO-3-CARBETOXYAMINO-6--PYRIDINE.|

---

JPH0568848U|1991-11-18|1993-09-17|京都機械工具株式会社|Tube wringer|

---

DE4327516A1|1993-08-17|1995-02-23|Asta Medica Ag|Primary and secondary neuroprotective effects in neurodegenerative diseases of flupirtine|

---

DE19625582A1|1996-06-27|1998-01-02|Asta Medica Ag|Use of flupirtine for the prophylaxis and therapy of diseases that are associated with an unphysiologically high cell death rate|

---

DE19716984A1|1997-04-23|1998-10-29|Asta Medica Ag|Process for the preparation of pure flupirtine maleate and its modification A|

---

US6187324B1|1998-08-11|2001-02-13|Kabushiki Kaisha Ogi Kogei|Cosmetic composition comprising at least one of Kumazasa extract and medicinal carbon|

---

US6821995B1|1999-12-01|2004-11-23|Duke University|Method of treating batten disease|

---

DE10327674A1|2003-06-20|2005-01-05|Awd.Pharma Gmbh & Co. Kg|Injectable dosage form of flupirtine|

---

US7741358B2|2005-04-14|2010-06-22|N.V. Organon|Crystal form of asenapine maleate|

---

US20080279930A1|2007-05-07|2008-11-13|Bernd Terhaag|Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof|

---

US8501778B2|2008-06-20|2013-08-06|Nhwa Pharma. Corporation|Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent|

---

US20110275679A1|2008-08-06|2011-11-10|Bionevia Pharmaceuticals, Inc.|Flupirtine hydrochloride maleic acid cocrystal|

---

DE102009023162B4|2009-05-29|2011-07-07|Corden PharmaChem GmbH, 68305|Process for the preparation of flupirtine|

---

CN102140077A|2010-01-28|2011-08-03|范扶民|Flupirtine A crystal form and preparation method thereof|

---

WO2012004391A1|2010-07-09|2012-01-12|K.H.S. Pharma Holding Gmbh|Process for the preparation of flupirtine maleate|

---

CN102241626B|2011-05-03|2013-07-03|北京华睿鼎信科技有限公司|Synthesis process of flupirtine maleate|

---

WO2013080215A1|2011-11-30|2013-06-06|Arch Pharmalabs Limited|An improved process for the preparation of flupirtine and pharmaceutically acceptable salts thereof|

---

CN103086963A|2013-01-29|2013-05-08|吉林修正药业新药开发有限公司|Synthetic method of flupirtine maleate A-type crystal compound and midbody|

---

CN104086481B|2014-07-18|2016-05-11|四川新斯顿制药股份有限公司|A kind of synthetic method of flupirtine maleate|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

DE3034638|1980-09-13|

---